Equifem-Balance
Natural health product licensed in Canada
- Licence holder
- Biologische Heilmittel Heel GmbH
- NPN or DIN-HM
- 80003141
- Status
- Active licence
- Licence date
- 3 April 2007
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Glycine max Extraction ratio : 10:1 Dry plant equivalent : 500 mg Potency : 40 % Isoflavones | 50 mg | Not calculated |
Non-medicinal ingredients
Maltodextrine, Hypromellose, Stéarate de magnésium, Eau purifiée, Dioxyde de silicium colloïdal, Cellulose, microcristalline, Sorbitol
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe féminin | Not specified | 3 Capsule | Not specified |
Uses authorised in Canada
Helps reduce symptoms associated with menopause in women. More specifically, these symptoms mainly include heat flushes (flashes), nocturnal sweats.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if pregnant or nursing. Consult a health care practitioner prior to use if have a history of kidney stones, a history of bladder cancer, renal failure or take extrogen replacement therapy, warfarin. Allergy to soy protein or one of the constituents of EQUIFEM-BALANCE.
- Effets indésirables connus
To date, no serious adverse effects related to short or long-term consumption of phytoestrogens were reported. Some have reported experiencing mild adverse effects such as nausea, headache, constipation, etc. If these occur, simply reduce your daily dosage or discontinue use of EQUIFEM-BALANCE. For other side effect concerns, consult your health care professional.
- Précautions et mises en garde
It is advisable to separate the intake of antibiotics and/or thyroid medication with EQUIFEM-BALANCE by 2-3 hours due to possible interactions. There is no conclusive literature stating that isoflavones interfere with oral contraceptives but if you are taking such medication, consult a health care practitioner before taking EQUIFEM-BALANCE. Due to possible estrogen receptor competition, phytoestrogen consumption is generally not recommended for patients taking tamoxifen or raloxifen, but may be taken in conjunction with HRT.
Source
Official Health Canada record, licence 80003141
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.